RE: Docket No. 98N-1265 May 18, 99

6244 '99 MAY 24 A11:46

Dear FDA:

It's come to my attention that the FDA under the auspices of the FDA Modernization Act of 1997 has drafted Section 503A which governs the practice of Pharmacy Compounding.

If left stand Section 503A will apparently eliminate Pharmacy Compounding and the right of the pharmacist to suggest alternatives or to ship Compounded drugs across state lines.

Its blatenly apparent Section 503A will benefit none but the large drug Companies and their patented drugs.

I ask that no restrictions be placed on my right to aquire Compounded drugs or the pharmacist right to make them, suggest them, or ship them across State lines.

Thank you,

Mrs. Mary Snyder
Box 64
Ashland, Pa 17921

98N-1265

C2610

MRS. MARY SNYDER
BOX 64
ASHLAND, PA. 17921

READING PA 196 44
PM
19 MAY
1995

USA H
First-Class Rate

Dockets Management Branch (HFA-305)
Food and Drug Administration
5630 Fishers Lane, Room 1061
Rockville, MD
20857-0003

20857+0003